A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer
NCT00649090
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
1549
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Neoplasms
Interventions
DRUG:
exemestane
Sponsor
Pfizer